

11 July 2011

2011/12 Multi-product Tender

PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply; and
- The draft process and terms and conditions for the 2011/12 Invitation to Tender.

PHARMAC welcomes all feedback on the 2011/12 Invitation to Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and would be considered by the PHARMAC Board (or Chief Executive acting under Delegated Authority) prior to making a decision on this proposal.

ALL RESPONSES ARE DUE BY 5PM, FRIDAY 19 AUGUST 2011

Feedback should be provided by submitting an email, fax or letter to:

Kyle Reid
Tender Analyst
PHARMAC
PO Box 10-254
Wellington 6143

Email: kyle.reid@pharmac.govt.nz

Fax: (04) 460 4995
DDI: (04) 916 7556

Details of the proposed 2011/12 multi-product tender

In accordance with PHARMAC's objective (to secure, for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided), PHARMAC is consulting on a proposal to tender certain pharmaceuticals for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB hospital pharmacies.

Attached to this letter (as Schedule One) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply and/or Hospital Supply Status. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a 'C' and/or 'H' next to it to indicate whether it is proposed to be tendered for community and/or hospital supply.

In general, the proposed Tender process would be similar to the 2010/11 Tender. A copy of the draft 2011/12 Invitation to Tender is available on our website: www.pharmac.govt.nz, or by contacting PHARMAC.

We are seeking feedback on the approach outlined in the following pages, in particular on:

- The proposed tender process and timeline;

- The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule One, including the impact of a brand switch on patients and clinical staff; and
- For hospital pharmaceuticals, your views on the appropriate Discretionary Variance (DV) Limit for each pharmaceutical, in the event you consider a 1% DV Limit to be clinically unacceptable.

Background

Since 1997 PHARMAC has been using the strategy of tendering pharmaceuticals for sole supply of pharmaceuticals for a fixed period of time. Regular tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. As in the past, the community and hospital tender processes would be run in unison, however, the pharmaceutical list for community and hospital supply may be different.

Key Aspects of Awarding a Tender for Community Pharmaceuticals:

- For community pharmaceuticals, the tender winning brand would be the only subsidised brand for up to approximately 3 years. The Sole Subsidised Supply period would conclude on 30 June 2015 for all Tenders awarded from the 2011/12 Invitation to Tender.
- No other brand of the pharmaceutical would be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Sole Subsidised Supply period.
- Other brands could continue to be marketed, sold and dispensed during the Sole Subsidised Supply Status period, but they would not receive a subsidy.
- Any pharmaceutical that currently carries a manufacturer's surcharge (that is, the additional patient charge above that of the patient co-payment) would become fully subsidised if a tender was awarded for that pharmaceutical.

Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals:

- For DHB hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (subject to any allowance for alternative brands under the agreed DV Limits) for up to approximately 3 years. The Hospital Supply Status period would conclude on 30 June 2015 for all tenders awarded from the 2011/12 Invitation to Tender.
- No other brand of the pharmaceutical would be listed in Section H of the Pharmaceutical Schedule during the Hospital Supply Status period.

Tender Timelines

This year we are proposing similar timelines to the 2010/11 Tender. In 2011, this has allowed us to consider and award bids earlier, giving the market and suppliers more notice of brand changes to better inform stock management. The proposed timelines for the 2011/12 Tender are as follows:

Date	Event
11 July 2011	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
05 August 2011	Final date for receipt of Alternative Commercial Proposals (ACPs) from suppliers by PHARMAC.
19 August 2011	Final date for all consultation to be received.

05 September 2011	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September 2011	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Decision Criteria and enters into provisional contracts with suppliers where appropriate.
September/October 2011	Consultation and Board decisions on Alternative Commercial Proposals.
Early November 2011	2011/12 Invitation to Tender issued.
21 December 2011	Invitation to Tender closes.
From end of January 2012	Board decisions on the first Tender winners announced.

Contractual obligations for suppliers

A copy of the draft terms and conditions which would form the terms of the 2011/12 Tender contract is available on the PHARMAC website: www.pharmac.govt.nz, or by phoning PHARMAC on 0800 66 00 50.

Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from 2009/10 Tender and the 2010/11 Tender prior to issuing the 2011/12 Invitation to Tender.

Should any unresolved Tender Bids be declined, PHARMAC would consider including those pharmaceuticals in the 2011/12 Invitation to Tender. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule One.

Distribution of Consultation Documents

Although this consultation letter has been widely distributed, should you consider that a particular person, group or agency should receive this letter and/or future tender documents, please feel free to contact PHARMAC or refer it on directly (note, all tender documents and consultations are also available from our website at www.pharmac.govt.nz/consultation). We also invite any person or group to contact PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter.

Tender items subject to Special Authority criteria

We are proposing to allow bids for both the current access criteria and for widened access criteria (e.g. with no Special Authority (SA) criteria) for some products currently subject to SA restrictions.

In previous tenders suppliers have indicated that they may be able to offer better pricing if they have certainty that SA criteria would be removed following a tender being awarded. Allowing bids for both levels of access would mean that suppliers would be able to offer their best pricing for both access levels.

If we did proceed with this approach in the 2011/12 Tender, only one option would be awarded (i.e. for either the current access criteria or widened access criteria), although, PHARMAC would retain the discretion to subsequently widen access at a later date if the tender were awarded for the current access criteria. The removal of SA criteria may be subject to PHARMAC taking clinical advice on the appropriateness of removing criteria.

Examples of products where we are considering allowing bids under both the current access criteria and widened access criteria are capecitabine, irinotecan and vinorelbine, included in Schedule Two of the draft 2011/12 Tender.

Schedule One: Possible pharmaceuticals for tender for sole supply

Order of pharmaceuticals in this Schedule

Pharmaceuticals have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers for your ease of reference. Pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one group.

Therapeutic Group	Page Numbers
Alimentary Tract and Metabolism	6 - 7
Blood and Blood Forming Organs	7 - 8
Cardiovascular System	8 - 9
Dermatologicals	9 - 11
Genito-Urinary System	11
Hormone Preparations – Systemic excluding contraceptives	11 - 12
Infections – Agents for Systemic Use	12 - 14
Musculoskeletal System	14
Nervous System	15 - 18
Oncology and Immunosuppressants	18 - 21
Respiratory System and Allergies	21 - 22
Sensory Organs	22 - 23

Information provided for each pharmaceutical

For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 July 2011;
- the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2011*.
- an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2011 by the relevant listed unit subsidy as at 1 July 2011); and
- comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

* The market data for the year ended 30 June 2011 provided has not yet been finalised; however, finalised data would be captured in the final 2011/12 Tender.

Explanation of terms, symbols and abbreviations

Most terms and abbreviations used are self explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft pharmaceutical list:

Symbol	Explanation
Underlined	Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2012 unless otherwise stated in the Comments column and a listing of a new brand could only occur after that date.
C	To be tendered for Sole Subsidised Supply Status (community pharmaceuticals).
H	To be tendered for Hospital Supply Status (DHB hospital pharmaceuticals).
PCT	A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project.
+	PHARMAC has been advised of the existence of a patent.
*	There is no fully funded product available for this line item (in relation to community supply).

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item

Units

Cost

Unit Subsidy

DV Limit

Comments

Alimentary Tract and Metabolism

Acarbose

<u>Tab 50 mg</u>	1,349,106	\$247,336	\$0.1833	C H	1%
<u>Tab 100 mg</u>	419,055	\$124,320	\$0.2967	C H	1%

Atropine Sulphate

<u>Inj 600 mcg, 1 ml</u>	64,736	\$67,325	\$1.0400	C H	1%
--------------------------	--------	----------	----------	-----	----

Calcitriol

<u>Cap 0.25 mcg</u>	1,992,104	\$201,203	\$0.1010	C H	1%
<u>Cap 0.5 mcg</u>	462,894	\$86,715	\$0.1873	C H	1%

Chlorhexidine gluconate

Mouthwash 0.2%	2,596,854	\$50,249	\$0.0194	C H	1%
----------------	-----------	----------	----------	-----	----

Cholecalciferol

Tab 1.25 mg (50,000 iu)	2,015,516	\$1,303,367	\$0.6467	C H	1%
-------------------------	-----------	-------------	----------	-----	----

Glipizide

Tab 5 mg	14,523,763	\$508,332	\$0.0350	C H	1%
----------	------------	-----------	----------	-----	----

Glycerol

Suppos greater than 3 g	223,766	\$67,130	\$0.3000	C H	1%
-------------------------	---------	----------	----------	-----	----

Hydrocortisone Acetate

<u>Rectal foam 10%, CFC-free</u>	206,440	\$225,029	\$1.0900	C H	1%
----------------------------------	---------	-----------	----------	-----	----

Hydroxocobalamin

<u>Inj 1 mg per ml, 1 ml</u>	260,669	\$534,371	\$2.0500	C H	1%
------------------------------	---------	-----------	----------	-----	----

Lansoprazole

Cap 15 mg	1,138,500	\$142,313	\$0.1250	C H	1%	A tender would not be implemented prior to September 2012
Cap 30 mg	3,049,230	\$506,390	\$0.1661	C H	1%	A tender would not be implemented prior to September 2012

L-Carnitine

Inj 200 mg per ml				C H	1%	Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria.
Oral liquid 500 mg per 15 ml				C H	1%	Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria.
Powder				C H	1%	Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria.
Tab 300 mg - 500 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule. Listing may be subject to Special Authority criteria.

Mesalazine

<u>Enema 1 g per 100 ml</u>	54,805	\$359,834	\$6.5657	C H	1%
-----------------------------	--------	-----------	----------	-----	----

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Mesalazine						
Tab EC 500 mg	148,439	\$73,477	\$0.4950	C H	1%	
Metformin Hydrochloride						
<u>Tab immediate-release 500 mg</u>	91,290,791	\$1,477,085	\$0.0162	C H	1%	
<u>Tab immediate-release 850 mg</u>	16,607,503	\$443,088	\$0.0267	C H	1%	
Miconazole						
Oral gel 20 mg per g	637,292	\$138,611	\$0.2175	C H	1%	
Pioglitazone						
<u>Tab 15 mg</u>	544,130	\$50,721	\$0.0932	C H	1%	
<u>Tab 30 mg</u>	468,410	\$87,492	\$0.1868	C H	1%	
<u>Tab 45 mg</u>	400,807	\$111,653	\$0.2786	C H	1%	

Blood and Blood Forming Organs

Atorvastatin						
Tab 10 mg	8,169,186	\$4,988,650	\$0.6107	C H	1%	Confidential rebate exists. A tender would not be implemented prior to 1 June 2012.
Tab 20 mg	13,404,512	\$11,930,016	\$0.8900	C H	1%	Confidential rebate exists. A tender would not be implemented prior to 1 June 2012.
Tab 40 mg	13,912,170	\$17,167,618	\$1.2340	C H	1%	Confidential rebate exists. A tender would not be implemented prior to 1 June 2012.
Tab 80 mg	1,985,589	\$7,313,586	\$3.6833	C H	1%	Confidential rebate exists. A tender would not be implemented prior to 1 June 2012.
Bezafibrate						
Tab 200 mg	1,161,894	\$125,872	\$0.1083	C H	1%	
Tab long-acting 400 mg	6,349,031	\$1,206,316	\$0.1900	C H	1%	
Enoxaparin Sodium						
<u>Inj 20 mg per 0.2 ml</u>	6,812	\$26,703	\$3.9200	C H	1%	
<u>Inj 40 mg per 0.4 ml</u>	70,735	\$369,944	\$5.2300	C H	1%	
<u>Inj 60 mg per 0.6 ml</u>	28,422	\$224,107	\$7.8850	C H	1%	
<u>Inj 80 mg per 0.8 ml</u>	44,855	\$471,516	\$10.5120	C H	1%	
<u>Inj 100 mg per ml, 1 ml</u>	58,482	\$790,677	\$13.5200	C H	1%	
<u>Inj 120 mg per 0.8 ml</u>	35,337	\$593,662	\$16.8000	C H	1%	
<u>Inj 150 mg per ml, 1 ml</u>	21,582	\$414,374	\$19.2000	C H	1%	
Heparin Sodium						
Inj 100 iu per ml, 250 ml				H	1%	
Heparinised Saline						
Inj 100 iu per ml, 2 ml ampoule				H	1%	
Inj 100 iu per ml, 5 ml ampoule				H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Hydroxyethyl Starch 130/0.4					
<u>Inj 6%</u>				H 1%	
Hydroxyethyl Starch 200/0.5					
<u>Inj 6%</u>				H 1%	
Potassium Chloride					
<u>Tab long-acting 600 mg</u>	10,235,670	\$358,248	\$0.0350	C H 1%	
Tranexamic Acid					
<u>Inj 100 mg per ml, 5 ml</u>				H 1%	

Cardiovascular System

Atenolol

<u>Tab 50 mg</u>	6,949,334	\$85,894	\$0.0124	C H 1%
<u>Tab 100 mg</u>	2,704,806	\$58,045	\$0.0215	C H 1%

Clonidine

<u>Inj 150 mcg per ml, 1 ml</u>	10,798	\$33,366	\$3.0900	C H 1%
<u>Tab 25 mcg</u>	2,654,960	\$511,080	\$0.1925	C H 1%
<u>Tab 150 mcg</u>	539,110	\$177,906	\$0.3300	C H 1%
<u>TDDS 2.5 mg, 100 mcg per day</u>	46,088	\$268,463	\$5.8250	C H 1%
<u>TDDS 5 mg, 200 mcg per day</u>	13,059	\$107,084	\$8.2000	C H 1%
<u>TDDS 7.5 mg, 300 mcg per day</u>	9,436	\$97,191	\$10.3000	C H 1%

Diltiazem Hydrochloride

<u>Tab 30 mg</u>	641,943	\$29,529	\$0.0460	C H 1%
<u>Tab 60 mg</u>	365,906	\$31,102	\$0.0850	C H 1%
<u>Cap long-acting 120 mg</u>	8,735,834	\$1,264,075	\$0.1447	C H 1%
<u>Cap long-acting 180 mg</u>	7,447,403	\$1,613,852	\$0.2167	C H 1%
<u>Cap long-acting 240 mg</u>	5,283,655	\$1,526,976	\$0.2890	C H 1%

Enalapril

<u>Tab 5 mg</u>	3,562,631	\$78,378	\$0.0220	C H 1%
<u>Tab 10 mg</u>	3,524,700	\$95,559	\$0.0271	C H 1%
<u>Tab 20 mg</u>	3,394,992	\$122,220	\$0.0360	C H 1%

Felodipine

<u>Tab long-acting 2.5 mg</u>	9,453,744	\$3,270,995	\$0.3460	C H 1%
<u>Tab long-acting 5 mg</u>	15,941,345	\$1,900,563	\$0.1192	C H 1%
<u>Tab long-acting 10 mg</u>	11,509,413	\$1,994,965	\$0.1733	C H 1%

Furosemide

<u>Tab 40 mg</u>	36,605,391	\$393,508	\$0.0108	C H 1%
<u>Tab 500 mg</u>	246,100	\$123,050	\$0.5000	C H 1%

Glyceryl Trinitrate

<u>Inj 1 mg per ml, 5 ml</u>				H 1%
------------------------------	--	--	--	------

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Glyceryl Trinitrate					
<u>Inj 1 mg per ml, 50 ml</u>				H 1%	
<u>Inj 5 mg per ml, 10 ml</u>				H 1%	
Lisinopril					
<u>Tab 5 mg</u>	823,657	\$56,558	\$0.0687	C H 1%	
<u>Tab 10 mg</u>	887,820	\$69,842	\$0.0787	C H 1%	
<u>Tab 20 mg</u>	1,199,797	\$114,781	\$0.0957	C H 1%	
Nadolol					
<u>Tab 40 mg</u>	1,962,348	\$293,763	\$0.1497	C H 1%	
<u>Tab 80 mg</u>	620,894	\$137,776	\$0.2219	C H 1%	
Pindolol					
<u>Tab 5 mg</u>	227,995	\$12,312	\$0.0540	C H 1%	
<u>Tab 10 mg</u>	256,327	\$23,556	\$0.0919	C H 1%	
<u>Tab 15 mg</u>	105,971	\$14,624	\$0.1380	C H 1%	
Sotalol					
<u>Tab 80 mg</u>	4,109,964	\$226,048	\$0.0550	C H 1%	
<u>Tab 160 mg</u>	358,745	\$37,668	\$0.1050	C H 1%	
Timolol Maleate					
<u>Tab 10 mg</u>	138,978	\$14,662	\$0.1055	C H 1%	

Dermatologicals

Betamethasone Valerate

<u>Scalp app 0.1%</u>	2,894,313	\$208,969	\$0.0722	C H 1%	
-----------------------	-----------	-----------	----------	--------	--

Calamine

<u>Crm. aqueous. BP</u>	902,615	\$25,093	\$0.0278	C H 1%	
<u>Lotn. BP</u>	5,205,621	\$43,467	\$0.0084	C H 1%	

Calcipotriol

<u>Crm 50 mcg per g (pack size 30 g or less)</u>	42,780	\$28,805	\$0.6733	C H 1%	
<u>Crm 50 mcg per g (pack size greater than 30 g)</u>	1,458,700	\$821,540	\$0.5632	C H 1%	
<u>Oint 50 mcg per g (pack size 30 g or less)</u>	40,620	\$27,351	\$0.6733	C H 1%	
<u>Oint 50 mcg per g (pack size greater than 30 g)</u>	1,436,400	\$808,980	\$0.5632	C H 1%	
<u>Soln 50 mcg per ml (pack size 30 ml or less)</u>	43,080	\$29,036	\$0.6740	C H 1%	
<u>Soln 50 mcg per ml (pack size greater than 30 ml)</u>	238,140	\$134,113	\$0.5632	C H 1%	

Chlorhexidine

<u>Crm 1% obstetric</u>				H 1%	
-------------------------	--	--	--	------	--

Chlorhexidine Gluconate

<u>Handrub 0.5% - 1% with ethanol 70%</u>	2,389,438	\$21,983	\$0.0092	C	Chlorhexidine strengths from 0.5% to 1% would be considered
---	-----------	----------	----------	---	---

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Ciclopiroxolamine						
<u>Nail soln 8%</u>	80,403	\$456,000	\$5.6714	C		
Clobetasol Propionate						
<u>Crm 0.05% (pack size 30 g or less)</u>	2,781,830	\$322,692	\$0.1160	C H	1%	
<u>Oint 0.05% (pack size 30 g or less)</u>	2,779,609	\$322,435	\$0.1160	C H	1%	
<u>Scalp app 0.05%</u>	578,567	\$122,656	\$0.2120	C H	1%	
Crotamiton						
<u>Crm 10%</u>	560,138	\$106,146	\$0.1895	C H	1%	
Fluorouracil Sodium						
Crm 5%	554,491	\$734,423	\$1.3245	C H	1%	A tender would not be implemented prior to October 2012
Hydrocortisone Butyrate						
Lipocream 0.1% (pack size 30 g or less)	1,979,340	\$151,749	\$0.0767	C H	1%	A tender would not be implemented prior to November 2012
Lipocream 0.1% (pack size greater than 30 g)	17,313,700	\$1,327,384	\$0.0767	C H	1%	A tender would not be implemented prior to November 2012
Milky Emulsion 0.1% (pack size 30 g or less)				C H	1%	Not currently listed on the Pharmaceutical Schedule. A tender would not be implemented prior to November 2012.
Milky Emulsion 0.1% (pack size greater than 30 g)	1,598,597	\$109,504	\$0.0685	C H	1%	A tender would not be implemented prior to November 2012
Oint 0.1% (pack size 30 g or less)				C H	1%	Not currently listed on the Pharmaceutical Schedule. A tender would not be implemented prior to November 2012.
Oint 0.1% (pack size greater than 30 g)	1,938,341	\$132,776	\$0.0685	C H	1%	A tender would not be implemented prior to November 2012
Scalp lotn 0.1%	3,598,370	\$131,341	\$0.0365	C H	1%	A tender would not be implemented prior to November 2012
Hydrocortisone with Natamycin and Neomycin						
Crm 1% with natamycin 1% and neomycin sulphate 0.5%	2,302,991	\$428,356	\$0.1860	C H	1%	A tender would not be implemented prior to November 2012
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	848,073	\$157,742	\$0.1860	C H	1%	A tender would not be implemented prior to November 2012
Isotretinoin						
<u>Cap 10 mg</u>	1,340,876	\$361,143	\$0.2693	C H	1%	Information on appropriate use should be available on a website
<u>Cap 20 mg</u>	1,403,423	\$543,437	\$0.3872	C H	1%	Information on appropriate use should be available on a website
Mometasone Furoate						
<u>Crm 0.1% (pack size 30 g or less)</u>	280,315	\$44,477	\$0.1587	C H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Mometasone Furoate						
<u>Crm 0.1% (pack size greater than 30 g)</u>	2,810,260	\$445,895	\$0.1587	C H	1%	
<u>Oint 0.1% (pack size 30 g or less)</u>	173,760	\$27,570	\$0.1587	C H	1%	
<u>Oint 0.1% (pack size greater than 30 g)</u>	1,940,106	\$307,830	\$0.1587	C H	1%	
Oil in Water Emulsion						
Crm	57,990,643	\$324,748	\$0.0056	C H	1%	A tender would not be implemented until at least 1 August 2012.
Paraffin						
<u>White soft or yellow soft (pack size 30 g or less)</u>				H	1%	

Genito Urinary System

Alprostadil						
<u>Inj 0.5 mg per ml, 1 ml</u>				H	1%	
Intra-Uterine Device						
IUD - Short length	6,514	\$257,303	\$39.5000	C H	1%	Units aggregated for both lengths
IUD - Standard length	6,514	\$257,303	\$39.5000	C H	1%	Units aggregated for both lengths
Norethisterone						
<u>Tab 350 mcg</u>	10,338,814	\$880,030	\$0.0851	C		
Oxytocin						
<u>Inj 5 iu per ml, 1 ml</u>	858	\$1,019	\$1.1880	C H	1%	
<u>Inj 10 iu per ml, 1 ml</u>	5,035	\$7,532	\$1.4960	C H	1%	
<u>Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml</u>	2,911	\$5,892	\$2.0240	C H	1%	
Pregnancy Tests - HCG Urine						
<u>Urine diagnostic test</u>	425,767	\$242,687	\$0.5700	C H	1%	

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Cabergoline						
Tab 0.5 mg	62,400	\$514,800	\$8.2500	C H	1%	
Cyproterone Acetate						
<u>Tab 50 mg</u>	805,460	\$339,904	\$0.4220	C H	1%	
<u>Tab 100 mg</u>	35,188	\$29,206	\$0.8300	C H	1%	
Dexamethasone						
Tab 0.5 mg - 1 mg	419,267	\$67,418	\$0.1608	C H	1%	1 mg tablet units and subsidy shown. A 0.5 mg tablet is not currently listed in the Pharmaceutical Schedule.
Tab 4 mg	791,534	\$489,880	\$0.6189	C H	1%	
Ethinylestradiol						
<u>Tab 10 mcg</u>	363,573	\$63,989	\$0.1760	C		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Gestrinone						
Cap 2.5 mg	4,575	\$58,257	\$12.7338	C H	1%	
Hydrocortisone						
Tab 5 mg	2,874,266	\$240,001	\$0.0835	C H	1%	
Tab 20 mg	133,427	\$27,953	\$0.2095	C H	1%	
Methylprednisolone						
Tab 4 mg	31,408	\$15,255	\$0.4857	C H	1%	
Tab 100 mg	22,794	\$189,783	\$8.3260	C H	1%	
Methylprednisolone Acetate						
Inj 40 mg per ml, 1 ml	5,870	\$35,396	\$6.0300	C H	1%	
Methylprednisolone Acetate with Lignocaine						
Inj 40 mg per ml with lignocaine 1 ml	2,148	\$12,952	\$6.0300	C H	1%	
Methylprednisolone Sodium Succinate						
<u>Inj 40 mg per ml, 1 ml</u>	509	\$3,083	\$6.0560	C H	1%	
<u>Inj 62.5 mg per ml, 2 ml</u>	687	\$11,338	\$16.5036	C H	1%	
<u>Inj 500 mg</u>	128	\$2,662	\$20.8000	C H	1%	
<u>Inj 1 g</u>	71	\$3,022	\$42.5700	C H	1%	
Prednisolone Sodium Phosphate						
<u>Oral liq 5 mg per ml</u>	3,865,171	\$1,281,948	\$0.3317	C H	1%	
Testosterone Undecanoate						
<u>Cap 40 mg</u>	884,574	\$706,952	\$0.7992	C H	1%	
Infections - Agents for Systemic Use						
Aciclovir						
Cream 5%				C H	1%	Not currently listed on the Pharmaceutical Schedule
<u>Inj 250 mg</u>				H	1%	
Amoxicillin						
Grans for oral liq 125 mg per 5 ml	29,649,920	\$459,574	\$0.0155	C H	1%	
<u>Grans for oral liq 250 mg per 5 ml</u>	28,276,430	\$311,041	\$0.0110	C H	1%	
Amoxicillin Clavulanate						
<u>Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml</u>	10,232,449	\$225,114	\$0.0220	C H	1%	ASP
<u>Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml</u>	15,452,855	\$594,935	\$0.0385	C H	1%	ASP
<u>Inj 600 mg</u>				H	1%	
<u>Inj 1.2 g</u>				H	1%	
Amphotericin B						
<u>Liposomal inj 50 mg</u>				H	1%	
Azithromycin						
<u>Tab 500 mg</u>	107,799	\$320,702	\$2.9750	C H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Benzathine Benzylpenicillin							
Inj 1.2 mega u	7,200	\$226,800	\$31.5000	C H	1%	ASP	
Caspofungin							
<u>Inj 50 mg</u>				H	1%		
<u>Inj 70 mg</u>				H	1%		
Cephalexin Monohydrate							
<u>Grans for oral liq 125 mg per 5 ml</u>	151,572	\$12,884	\$0.0850	C H	1%		
<u>Grans for oral liq 250 mg per 5 ml</u>	293,319	\$33,732	\$0.1150	C H	1%		
Co-Trimoxazole							
Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	3,324,816	\$113,044	\$0.0340	C H	1%		
Efavirenz							
Cap 50 mg				+ C H	1%		
Cap 100 mg				+ C H	1%		
Cap 200 mg				+ C H	1%		
Tab 50 mg	2,738	\$14,450	\$5.2777	+ C H	1%		
Tab 200 mg	2,088	\$11,020	\$5.2777	+ C H	1%		
Tab 600 mg	228,554	\$3,618,695	\$15.8330	+ C H	1%		
Emtricitabine							
Cap 200 mg	245,880	\$2,517,811	\$10.2400	+ C H	1%		
Erythromycin Ethyl Succinate							
Grans for oral liq 200 mg per 5 ml	7,069,230	\$307,512	\$0.0435	C H	1%	ASP	
Grans for oral liq 400 mg per 5 ml	4,483,547	\$262,287	\$0.0585	C H	1%	ASP	
<u>Tab 400 mg</u>	4,871,360	\$825,696	\$0.1695	C H	1%		
Flucloxacillin							
<u>Grans for oral liq 125 mg per 5 ml</u>	6,209,212	\$193,727	\$0.0312	C H	1%	Bids would be accepted for either the sodium or magnesium salts	
<u>Grans for oral liq 250 mg per 5 ml</u>	7,735,625	\$274,615	\$0.0355	C H	1%	Bids would be accepted for either the sodium or magnesium salts	
Flucloxacillin Sodium							
<u>Cap 250 mg</u>	1,593,425	\$203,958	\$0.1280	C H	1%		
<u>Cap 500 mg</u>	11,035,657	\$2,427,845	\$0.2200	C H	1%		
Fluconazole							
<u>Inj 2 mg per ml, 50 ml</u>				H	1%		
Gentamicin Sulphate							
<u>Inj 40 mg per ml, 2 ml</u>	5,153	\$4,638	\$0.9000	C H	1%		
Hydroxychloroquine Sulphate							
<u>Tab 200 mg</u>	2,860,868	\$643,695	\$0.2250	C H	1%		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Isoniazid							
Tab 100 mg	240,528	\$48,106	\$0.2000	C H	1%	A tender would not be implemented prior to November 2012	
Nevirapine							
<u>Oral suspension 10 mg per ml</u>	10,993	\$6,163	\$0.5606	C H	1%		
<u>Tab 200 mg</u>	167,750	\$894,108	\$5.3300	C H	1%		
Nitrofurantoin							
Oral liq 25 mg per 5 ml				C H	1%	Not currently listed on the Pharmaceutical Schedule	
Tab 50 mg	1,795,060	\$398,503	\$0.2220	C H	1%		
Tab 100 mg	566,769	\$212,538	\$0.3750	C H	1%		
Ritonavir							
Cap 100 mg	90,389	\$130,494	\$1.4437	+ C H	1%		
Oral liq 80 mg per ml	0	\$0	\$1.1553	+ C H	1%		
Roxithromycin							
<u>Tab 150 mg</u>	2,511,083	\$450,991	\$0.1796	C H	1%	ASP	
<u>Tab 300 mg</u>	941,935	\$310,462	\$0.3296	C H	1%	ASP	

Musculoskeletal System

Baclofen							
<u>Inj 10 mg</u>				H	1%		
<u>Tab 10 mg</u>	3,602,772	\$171,132	\$0.0475	C H	1%		
Diclofenac Sodium							
<u>Tab EC 25 mg</u>	611,472	\$19,934	\$0.0326	C H	1%		
<u>Tab EC 50 mg</u>	4,541,303	\$193,460	\$0.0426	C H	1%		
Tab long-acting 75 mg	23,324,952	\$1,530,117	\$0.0656	C H	1%		
Tab long-acting 100 mg	3,455,177	\$436,873	\$0.1264	C H	1%		
Etidronate Disodium							
<u>Tab 200 mg</u>	1,117,632	\$267,673	\$0.2395	C H	1%		
Indomethacin							
Cap 25 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule	
Cap 50 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule	
Cap long-acting 75 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule	
Naproxen							
<u>Tab 250 mg</u>	1,933,579	\$91,652	\$0.0474	C H	1%		
<u>Tab 500 mg</u>	4,364,536	\$434,359	\$0.0995	C H	1%		
Quinine Sulphate							
<u>Tab 300 mg</u>	1,639,886	\$177,304	\$0.1081	C H	1%		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item

Units

Cost

Unit Subsidy

DV Limit

Comments

Nervous System

Aripiprazole

Tab 10 mg					H	1%	
Tab 15 mg					H	1%	
Tab 20 mg					H	1%	
Tab 30 mg					H	1%	

Atracurium Besylate

<u>Inj 10 mg per ml, 2.5 ml</u>					H	1%	
<u>Inj 10 mg per ml, 5 ml</u>					H	1%	

Bupivacaine Hydrochloride

<u>Inj 0.25%, 20 ml</u>					H	1%	
<u>Inj 0.5%, 10 ml</u>					H	1%	
<u>Inj 0.5%, 10 ml theatre pack</u>					H	1%	
<u>Inj 0.5%, 20 ml theatre pack</u>					H	1%	

Clomipramine Hydrochloride

Tab 10 mg	302,166	\$38,073	\$0.1260		C H	1%	
Tab 25 mg	1,883,291	\$163,470	\$0.0868		C H	1%	

Codeine Phosphate

Tab 15 mg	5,434,686	\$292,930	\$0.0539		C H	1%	A tender would not be implemented prior to November 2012
Tab 30 mg	20,111,116	\$1,659,167	\$0.0825		C H	1%	A tender would not be implemented prior to November 2012
Tab 60 mg	1,942,316	\$344,955	\$0.1776		C H	1%	A tender would not be implemented prior to November 2012

Cyclizine Hydrochloride

<u>Tab 50 mg</u>	1,155,093	\$183,660	\$0.1590		C H	1%	
------------------	-----------	-----------	----------	--	-----	----	--

Dexamphetamine Sulphate

Tab 5 mg	641,809	\$105,898	\$0.1650		C H	1%	A tender would not be implemented prior to November 2012
----------	---------	-----------	----------	--	-----	----	--

Donepezil hydrochloride

<u>Tab 5 mg</u>	639,394	\$54,775	\$0.0857		C H	1%	Recently listed on Pharmaceutical Schedule
<u>Tab 10 mg</u>	651,151	\$101,724	\$0.1562		C H	1%	Recently listed on Pharmaceutical Schedule

Dopamine

<u>Inj 40 mg per ml, 5 ml</u>					H	1%	
-------------------------------	--	--	--	--	---	----	--

Doxepin Hydrochloride

Cap 10 mg	1,660,537	\$87,012	\$0.0524		C H	1%	A tender would not be implemented until at least November 2012.
-----------	-----------	----------	----------	--	-----	----	---

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Doxepin Hydrochloride							
Cap 25 mg	2,238,223	\$122,207	\$0.0546	C H	1%	A tender would not be implemented until at least November 2012.	
Cap 50 mg	932,297	\$68,431	\$0.0734	C H	1%	A tender would not be implemented until at least November 2012.	
Cap 75 mg				C H	1%	Not currently listed. A tender would not be implemented until at least November 2012.	
Entacapone							
<u>Tab 200 mg</u>	690,619	\$801,118	\$1.1600	C H	1%		
Fentanyl							
<u>Inj 50 mcg per ml, 2 ml</u>	73,463	\$47,237	\$0.6430	C H	1%		
<u>Inj 50 mcg per ml, 10 ml</u>	11,424	\$19,204	\$1.6810	C H	1%		
Granisetron							
Tab 1 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction	
Lignocaine							
<u>Gel 2%</u>				H	1%		
Lignocaine Hydrochloride							
<u>Inj 1%, 2 ml</u>				H	1%		
<u>Inj 1%, 5 ml</u>				H	1%		
<u>Inj 1%, 20 ml</u>				H	1%		
<u>Inj 2%, 2 ml</u>				H	1%		
<u>Inj 2%, 5 ml</u>				H	1%		
<u>Inj 2%, 20 ml</u>				H	1%		
Lithium Carbonate							
Tab 250 mg	1,946,246	\$140,519	\$0.0722	C H	1%		
Tab 400 mg	289,100	\$39,029	\$0.1350	C H	1%		
Tab long-acting 400 mg	1,282,514	\$237,265	\$0.1850	C H	1%		
Methadone Hydrochloride							
<u>Oral liq 2 mg per ml</u>	1,852,661	\$55,117	\$0.0298	C H	1%		
<u>Oral liq 5 mg per ml</u>	23,246,976	\$645,104	\$0.0278	C H	1%		
<u>Oral liq 10 mg per ml</u>	3,408,625	\$152,536	\$0.0448	C H	1%		
Mirtazapine							
Tab 15 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule	
Tab 30 mg	629,445	\$461,572	\$0.7333	C H	1%		
Tab 45 mg	131,842	\$153,807	\$1.1666	C H	1%		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Moclobemide							
<u>Tab 150 mg</u>	1,322,067	\$183,053	\$0.1385	C H	1%		
<u>Tab 300 mg</u>	396,647	\$124,270	\$0.3133	C H	1%		
Morphine Hydrochloride							
<u>Oral liq 1 mg per ml</u>	5,986,436	\$264,600	\$0.0442	C H	1%		
<u>Oral liq 2 mg per ml</u>	683,564	\$39,715	\$0.0581	C H	1%		
<u>Oral liq 5 mg per ml</u>	823,661	\$60,333	\$0.0733	C H	1%		
<u>Oral liq 10 mg per ml</u>	557,546	\$60,076	\$0.1078	C H	1%		
Morphine Sulphate							
<u>Tab immediate release 10 mg</u>	1,556,437	\$435,802	\$0.2800	C H	1%		
<u>Tab immediate release 20 mg</u>	678,780	\$374,687	\$0.5520	C H	1%		
Nortriptyline hydrochloride							
Oral liq 10 mg per 5 ml				C H	1%	Not currently listed on the Pharmaceutical Schedule	
Tab 10 mg	6,550,532	\$389,102	\$0.0594	C H	1%		
Tab 25 mg	8,297,885	\$665,675	\$0.0802	C H	1%		
Ondansetron Hydrochloride							
<u>Inj 2 mg per ml, 2 ml</u>				H	1%		
<u>Inj 2 mg per ml, 4 ml</u>				H	1%		
Oxycodone Hydrochloride							
Cap 5 mg	1,986,372	\$281,072	\$0.1415	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
Cap 10 mg	1,264,947	\$352,920	\$0.2790	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
Cap 20 mg	531,908	\$259,837	\$0.4885	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
Inj 10 mg per ml, 1 ml	35,454	\$102,108	\$2.8800	C H	1%		
Inj 10 mg per ml, 2 ml	53,872	\$310,303	\$5.7600	C H	1%		
Oral liq 5 mg per 5 ml	1,480,024	\$66,305	\$0.0448	C H	1%		
Tab controlled-release 5 mg	1,200,966	\$450,963	\$0.3755	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
Tab controlled-release 10 mg	2,502,402	\$1,393,838	\$0.5570	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
Tab controlled-release 20 mg	1,627,540	\$1,540,467	\$0.9465	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
Tab controlled-release 40 mg	490,424	\$816,311	\$1.6645	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	
Tab controlled-release 80 mg	202,375	\$587,191	\$2.9015	C H	1%	Product should be supplied in blister packs or bottle with child-resistant cap.	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Pancuronium bromide					
<u>Inj 2 mg per ml, 2 ml</u>				H 1%	
Paracetamol					
Suppos 500 mg	128,785	\$52,802	\$0.4100	C H 1%	A tender would not be implemented prior to November 2012
Pethidine Hydrochloride					
Tab 50 mg	244,205	\$78,146	\$0.3200	C H 1%	A tender would not be implemented prior to November 2012. Product should be supplied in blister packs or bottle with child-resistant cap.
Tab 100 mg	94,432	\$39,661	\$0.4200	C H 1%	A tender would not be implemented prior to November 2012. Product should be supplied in blister packs or bottle with child-resistant cap.
Phenobarbitone					
Oral liq 15 mg per 5 ml				C H 1%	Not currently listed on the Pharmaceutical Schedule. Alcohol free preparation preferred.
Tab 15 mg	93,678	\$4,684	\$0.0500	C H 1%	A tender would not be implemented prior to November 2012
Tab 30 mg	698,500	\$36,322	\$0.0520	C H 1%	A tender would not be implemented prior to November 2012
Phenobarbitone Sodium					
Inj 200 mg per ml, 1 ml				H 1%	
Pizotifen					
<u>Tab 500 mcg</u>	1,357,566	\$286,446	\$0.2110	C H 1%	
Rocuronium					
<u>Inj 10 mg per ml, 5 ml</u>				H 1%	
Selegiline Hydrochloride					
<u>Tab 5 mg</u>	190,971	\$30,670	\$0.1606	C	
Tropisetron					
<u>Cap 5 mg</u>	2,041	\$31,599	\$15.4820	C H 1%	
Inj 1 mg per ml, 2 ml				H 1%	

Oncology Agents and Immunosuppressants

Capecitabine (current access)					
Tab 150 mg	688,630	\$4,045,701	\$5.8750	C H 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Capecitabine (current access)							
Tab 500 mg	110,540	\$211,868	\$1.9167	C H	1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
Capecitabine (widened access)							
Tab 150 mg	688,630	\$4,045,701	\$5.8750	C H	1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
Tab 500 mg	110,540	\$211,872	\$1.9167	C H	1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
Carboplatin							
<u>Inj 10 mg per ml, 5 ml</u>					H PCT 1%		
<u>Inj 10 mg per ml, 15 ml</u>					H PCT 1%		
<u>Inj 10 mg per ml, 45 ml</u>					H PCT 1%		
<u>Inj 10 mg per ml, 100 ml</u>					H PCT 1%		
Cyclosporin							
Cap 25 mg	1,170,509	\$1,392,906	\$1.1900	C H	1%	Bids would need to be for a microemulsion formulation.	
Cap 50 mg	384,922	\$912,573	\$2.3708	C H	1%	Bids would need to be for a microemulsion formulation.	
Cap 100 mg	546,590	\$2,591,711	\$4.7416	C H	1%	Bids would need to be for a microemulsion formulation.	
<u>Inf 50 mg per ml, 5 ml</u>					H 1%		
Oral liq 100 mg per ml	18,432	\$97,384	\$5.2834	C H	1%		
Doxorubicin							
<u>Inj 10 mg</u>					H PCT 1%		
<u>Inj 50 mg</u>					H PCT 1%		
<u>Inj 100 mg</u>					H PCT 1%		
<u>Inj 200 mg</u>					H PCT 1%		
Epirubicin							
<u>Inj 2 mg per ml, 5 ml</u>					H PCT 1%		
<u>Inj 2 mg per ml, 25 ml</u>					H PCT 1%		
<u>Inj 2 mg per ml, 50 ml</u>					H PCT 1%		
<u>Inj 2 mg per ml, 100 ml</u>					H PCT 1%		
Idarubicin Hydrochloride							
<u>Cap 5 mg</u>					H PCT 1%		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Idarubicin Hydrochloride							
<u>Cap 10 mg</u>					H PCT 1%		
<u>Inj 5 mg</u>					H PCT 1%		
<u>Inj 10 mg</u>					H PCT 1%		
Imatinib Mesylate							
Tab 100 mg	469,635	\$18,785,400	\$40.0000	+ C H	1%	Bids would be accepted for either tablets or capsules. Tender agreement may be subject to a Special Authority restriction	
Irinotecan (current access)							
<u>Inj 20 mg per ml, 2 ml</u>					H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
<u>Inj 20 mg per ml, 5 ml</u>					H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
Irinotecan (widened access)							
<u>Inj 20 mg per ml, 2 ml</u>					H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
<u>Inj 20 mg per ml, 5 ml</u>					H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.	
Letrozole							
<u>Tab 2.5 mg</u>	478,088	\$423,108	\$0.8850	C H	1%		
Megestrol Acetate							
<u>Tab 160 mg</u>	44,413	\$85,747	\$1.9307	C H	1%		
Methotrexate							
<u>Tab 2.5 mg</u>	1,999,584	\$347,928	\$0.1740	C H	1%		
<u>Tab 10 mg</u>	456,729	\$373,878	\$0.8186	C H	1%		
Mycophenolate Mofetil							
Cap 250 mg	538,432	\$457,667	\$0.8500	C H	1%		
Inj 500 mg				H	1%		
Powder for oral liq 1 g per 5 ml	34,215	\$59,099	\$1.7273	C H	1%		
Tab 500 mg	860,272	\$1,462,462	\$1.7000	C H	1%		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Octreotide (somatostatin analogue)					
LAR inj 10 mg	200	\$354,500	\$1,772.5000	C H 1%	
LAR inj 20 mg	1,346	\$3,174,878	\$2,358.7500	C H 1%	
LAR inj 30 mg	996	\$2,939,445	\$2,951.2500	C H 1%	
Oxaliplatin					
<u>Inj 50 mg</u>				H PCT 1%	
<u>Inj 100 mg</u>				H PCT 1%	
Pipobroman					
Tab 25 mg				H PCT 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction.
Thalidomide					
Cap 50 mg				H PCT 1%	
Cap 100 mg				H PCT 1%	
Vinorelbine (current access)					
<u>Inj 10 mg per ml, 1 ml</u>				H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.
<u>Inj 10 mg per ml, 5 ml</u>				H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.
Vinorelbine (widened access)					
Inj 10 mg per ml, 1 ml				H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.
Inj 10 mg per ml, 5 ml				H PCT 1%	PHARMAC would only award a tender for either current access or widened access. Should a tender be awarded for current access, PHARMAC reserves the right to widen access at a later date.
Zoledronic Acid					
Inj 4 mg				H 1%	

Respiratory System and Allergies

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Fluticasone propionate							
Metered aqueous nasal spray, 50 mcg per dose	28,026,549	\$3,115,618	\$0.1112	C H	1%	A confidential rebate currently exists. A tender would not be implemented prior to December 2012	
Pholcodine							
Oral liquid 1 mg per ml				H	1%		
Promethazine Hydrochloride							
<u>Oral liq 5 mg per 5 ml</u>	4,744,483	\$147,079	\$0.0310	C H	1%		
Tab 10 mg	1,536,704	\$83,597	\$0.0544	C H	1%		
Tab 25 mg	1,474,790	\$130,961	\$0.0888	C H	1%		
Salbutamol							
<u>Nebuliser soln, 1 mg per ml, 2.5 ml</u>	350,201	\$61,635	\$0.1760	C H	1%		
<u>Nebuliser soln, 2 mg per ml, 2.5 ml</u>	888,907	\$164,448	\$0.1850	C H	1%		
Salbutamol with Ipratropium Bromide							
<u>Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml</u>	808,984	\$173,527	\$0.2145	C H	1%		
Sodium Cromoglycate							
<u>Nasal spray, 4%</u>	59,247	\$42,685	\$0.7205	C			
Theophylline							
Oral liq 80 mg per 15 ml	95,919	\$2,973	\$0.0310	C H	1%		
Tab long-acting 250 mg	1,050,831	\$226,034	\$0.2151	C H	1%		

Sensory Organs

Bimatoprost							
Eye Drops 0.03%	202,675	\$1,317,388	\$6.5000	C H	1%		
Bimatoprost with timolol							
Eye Drops 0.03% with timolol 0.5%				+ C H	1%	Not currently listed on the Pharmaceutical Schedule	
Brinzolamide							
Eye Drops 1%	189,629	\$370,535	\$1.9540	C H	1%		
Chloramphenicol							
<u>Eye drops 0.5%</u>	1,898,902	\$243,059	\$0.1280	C H	1%	Single dose presentation would not be a DV Pharmaceutical	
<u>Eye oint 1%</u>	555,492	\$329,129	\$0.5925	C H	1%		
Fluorometholone							
<u>Eye drops 0.1%</u>	57,213	\$46,343	\$0.8100	C H	1%		
Latanoprost							
<u>Eye drops 50 mcg per ml</u>	586,590	\$2,287,701	\$3.9000	C H	1%		
Latanoprost with timolol							
Eye drops 50 mcg per ml with timolol 0.5%				+ C H	1%	Not currently listed on the Pharmaceutical Schedule	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Sodium Hyaluronate						
<u>Ophthalmic inj 14 mg per ml</u>					H 1%	
<u>Ophthalmic soln 10 mg per ml</u>					H 1%	
Travoprost						
Eye drops 0.004%	95,788	\$747,146	\$7.8000		C H 1%	
Travoprost with timolol						
Eye drops 0.004% with timolol 0.5%					+ C H 1%	Not currently listed on the Pharmaceutical Schedule